Overview

Despite significant advances in oncology, there is still a large unmet need in treating patients with solid tumors, especially those with advanced disease. Our approach begins with our proprietary computational discovery platform to identify new drug targets and biological pathways that could enhance anti-cancer immune responses. With these new targets in hand and a deep understanding of their underlying biology, we are advancing new therapeutics and optimizing their combination to expand immuno-oncology treatment options to cancer patients who are not responsive to currently available drugs.

 

Programs (mechanism of action)	Stage and Indication	Sponsor/ Partner
MAIA-ovarian COM701 maintenance therapy (anti-PVRIG antibody)	Adaptive platform trial: relapsed platinum sensitive ovarian cancer, sub-trial 1 randomized vs. placebo
COM701 + COM902 + pembrolizumab (anti-PVRIG, TIGIT, PD-1 antibodies)	Proof of Concept: platinum resistant ovarian cancer
Rilvegostomig monotherapy and combination trials (anti-PD1/TIGIT antibody) TIGIT component derived from COM902	5 Phase 3: non-small-cell-lung-cancer (NSCLC) 5 Phase 3: gastrointestinal cancer (GI) 1 Phase 3: endometrial cancer 14 Phase 1 or 2: NSCLC, Gl cancer, others
GS-0321 ongoing (anti-IL18BP antibody)	Phase 1: solid tumors
Early-stage pipeline ongoing (potential first-in-class drugs/new mechanism of actions)	Undisclosed

CT. gov; AstraZeneca Clinical Trial appendix
GS-0321: Compugen responsible for predinical development and the first- in-human Phase 1 trial evaluating the safety and tolerability of GS- 0321.
Thereafter Gile ad will have the sole right to develop and commercialize GS- 0321.